These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26637735)

  • 21. Recent advances in myeloma treatment.
    Schots R
    Transfus Apher Sci; 2011 Apr; 44(2):223-9. PubMed ID: 21349768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The rationale of autologous bone marrow transplantation.
    Mandelli F; Meloni G
    Bone Marrow Transplant; 1991; 7 Suppl 2():66-7. PubMed ID: 1878725
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
    Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
    Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of multiple myeloma.
    Alexanian R; Dimopoulos M
    N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
    [No Abstract]   [Full Text] [Related]  

  • 26. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial treatment of transplant candidates with multiple myeloma.
    Moreau P; Touzeau C
    Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A practical approach to relapsed multiple myeloma.
    Mikhael JR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):262-7. PubMed ID: 25696865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of multiple myeloma. Theoretical principles and clinical procedures].
    Heyll A; Wolf HH; Aul C; Schmitt G; Schneider W
    Dtsch Med Wochenschr; 1993 Jul; 118(26):986-94. PubMed ID: 8519234
    [No Abstract]   [Full Text] [Related]  

  • 31. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
    Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current results of chemotherapy in multiple myeloma].
    Sezaki T
    Gan To Kagaku Ryoho; 1989 May; 16(5):1997-2003. PubMed ID: 2658839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of myelomatosis.
    Galton DA; Brito-Babapulle F
    Eur J Haematol; 1987 Nov; 39(5):385-98. PubMed ID: 2446915
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy of multiple myeloma and its complications].
    Avvisati G; Pulsoni A; Petrucci MT; Tribalto M
    Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapsed and refractory multiple myeloma: new therapeutic strategies.
    Gentili S; Lonial S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.